Unlike general health products stocked in every health store, CJC-1295 is distributed via a dedicated online market that Rus residents access almost entirely online. This global online supply model is actually an advantage for quality — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide gives Rus researchers the framework to assess vendor quality rigorously and source research-grade CJC-1295 with confidence.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Rus comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger dangerous inflammatory cascades even at trace quantities. Community reputation in research forums is a complementary signal to COA verification — vendors with consistently positive reports over 12+ months have earned that standing through repeat quality delivery. For Rus researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Rus
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in CJC-1295 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the key safeguard. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
